Clinical Trials Browser

Phase 2 × Has results × IMC-18F1 × Clear all

NCT01282463 2019-09-09

Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma

Phase 2 Completed

148 enrolled 19 charts

Carcinoma, Renal Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT01234402 2019-08-14

Study of Icrucumab (IMC-18F1) or Ramucirumab Drug Product (DP) in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients

Phase 2 Completed

153 enrolled 22 charts

Breast Neoplasms

NCT01111604 2019-08-06

A Study of Ramucirumab or Icrucumab in Colorectal Cancer

Phase 2 Completed

158 enrolled 17 charts

Gastrointestinal

Adenocarcinoma, Colonic Neoplasms, Rectal Neoplasms